PolarCool

Med-tech company PolarCool AB (publ.) announces a two-year extension of its agreement with HC Davos for the continued use of the PolarCap® through 2027

The Swiss ice hockey club has successfully integrated PolarCap® into its concussion management protocol over the past four seasons, using the technology to support faster recovery and improved player outcomes following head injuries.

PolarCool develops and markets PolarCap®, a medical device that improves recovery after concussions through controlled cooling therapy. The product is primarily used in sports with an elevated risk of head injuries, such as ice hockey, rugby, football (soccer), and handball.

The renewed agreement with HC Davos further strengthens PolarCool's presence in the Swiss market, where the company already collaborates with several leading teams in the top ice hockey league.

HC Davos' Team Doctor, Dr. Walter Kistler, comments;

-We at HC Davos are pleased to continue using PolarCap® as part of our acute concussion management routines. The clinical evidence is convincing, and our own experience after four years of use confirms the published robust results from the 5-year study in Swedish ice hockey.

PolarCool's CEO, Erik Andersson, comments;

-HC Davos' extension demonstrates both trust and confirmation of PolarCap®'s clinically positive effects. We see yet another important step in our continued establishment in the Swiss hockey market and as an opportunity to expand cooperation in other priority markets such as rugby, football, and handball.

The agreement with HC Davos is an important part of PolarCool's goal to increase its presence in the European market, even if the financial impact of individual agreements is limited.